BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis Secures New Financing to Bolster Commercial Growth

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

On November 16, 2026, Valbiotis, a French laboratory focused on cardiometabolic health, announced a significant financial boost. The company has secured €1.65 million in non-dilutive bank loans from Société Générale, BNP Paribas, and Bpifrance. Additionally, a factoring agreement with BNP Paribas Factor has been established. These financial resources aim to support the expansion of Valbiotis' commercial activities, particularly in pharmacies, without diluting shareholder value.

The new financing includes two loans of €600,000 each from Société Générale and BNP Paribas, both on four-year terms, and a €450,000 loan from Bpifrance with an eight-year term. This arrangement demonstrates the confidence of long-term financial partners in Valbiotis' growth strategy.

Supplementing an existing cash reserve of €11.7 million as of June 30, 2026, these funds enable Valbiotis to prioritize the commercialization of its products while ensuring financial agility. The company aims for a robust international presence in the cardiometabolic health arena.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news